Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.04. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
28.03. | PROVECTUS BIOPHARMACEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
27.03. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium | 53 | GlobeNewswire (Europe) | New Provectus Spinout Company Would Commercialize Combination Therapy of University's Light Source Medical Device and Provectus's Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,... ► Artikel lesen | |
26.03. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
12.03. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines | 223 | GlobeNewswire (Europe) | KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB: PVCT) today announced that the United States Patent and Trademark Office... ► Artikel lesen | |
22.02. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
15.02. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
15.02. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call | 3 | GlobeNewswire (USA) | ||
18.12.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant | 185 | GlobeNewswire (Europe) | KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled... ► Artikel lesen | |
15.11.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma | 333 | GlobeNewswire (Europe) | KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal... ► Artikel lesen | |
14.11.23 | PROVECTUS BIOPHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.11.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma | 522 | GlobeNewswire (Europe) | KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal... ► Artikel lesen | |
28.06.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine S | 207 | GlobeNewswire (Europe) | KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of... ► Artikel lesen | |
26.06.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio | 322 | GlobeNewswire (Europe) | KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company's shareholders have approved the proposals of Provectus's Board of Directors (Board) to seek... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 119,06 | +2,46 % | Einmalige Chance? Die Aktien von Eli Lilly und Novo Nordisk haben noch mehr Potenzial als gedacht | Für die Pharmariesen Eli Lilly und Novo Nordisk läuft es schon länger rund. Die aktuellen Blockbuster-Medikamente könnten aber noch erfolgreicher werden als ohnehin schon. Sollten Anleger jetzt noch... ► Artikel lesen | |
AURORA CANNABIS | 6,290 | +0,48 % | Investors Shuffle Stock Positions In Aurora Cannabis: Beyond Earnings, Liquidity Looks Appealing | ||
CANOPY GROWTH | 8,370 | +0,48 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
TILRAY BRANDS | 1,670 | +0,09 % | Tilray Aktie: Achterbahnfahrt setzt sich fort | Zum Ende einer bewegten Woche notiert die Aktie des Unternehmens Tilray bei 1.62 €, was einer leichten Veränderung von -0.09% im Vergleich zur Vorwoche entspricht. Die Hoffnungen auf Lockerungen der... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 371,55 | +0,04 % | Vertex Pharmaceuticals: Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | KALYDECO is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - Vertex Pharmaceuticals... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,170 | +1,49 % | TAAT Global Alternatives Inc (2): TAAT Global settles $80,415 debt with shares | ||
CRONOS GROUP | 2,478 | +2,14 % | Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders | ||
DIGICANN VENTURES | 0,002 | -63,64 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 26.01.2024 | The following instruments on XETRA do have their first trading 26.01.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.01.2024
Aktien
1 KYG7006A1094 Perfect Corp.
2 JP3501950004... ► Artikel lesen | |
SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,027 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2024ISIN NameAU000000AC89 AUSCANN... ► Artikel lesen | |
ORGANIGRAM | 1,726 | -1,03 % | ORGANIGRAM HOLDINGS INC. - 6-K, Report of foreign issuer | ||
GREEN THUMB INDUSTRIES | 11,590 | +0,70 % | Green Thumb Industries Inc: Green Thumb to open Rise Dispensary Wesley Chapel | ||
MYDECINE INNOVATIONS GROUP | 0,010 | -4,76 % | Mydecine Innovations Group Inc.: Mydecine Announces Intention to Refile Certain Financial Statements and Applies for Management Cease Trade Order | ||
SINOPHARM | 2,615 | +1,28 % | SINOPHARM (01099): 2023 SUSTAINABILITY REPORT | ||
ASTRIA THERAPEUTICS | 9,000 | +7,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen |